RESOMER LC 703 S is a medical-grade bioresorbable copolymer of L-lactide and ε-caprolactone supplied as white to off-white granules. The designation encodes a nominal 70:30 molar ratio of L-lactide to ε-caprolactone. Inherent viscosity is controlled within 1.5–2.5 dL/g when measured at 0.1% w/v in chloroform at 25 °C using an Ubbelohde capillary viscometer according to DIN EN ISO 1628-1. Monomer sequence distribution and residual monomer content are verified by NMR and HPLC; residual lactide plus ε-caprolactone is limited to ≤1.0%, while residual solvents are controlled to ≤0.5% by headspace gas chromatography. Tin catalyst residue is limited to ≤200 ppm by inductively coupled plasma mass spectrometry, and sulphated ash is ≤0.1% under Ph. Eur. 2.4.14. The polymer is amorphous under ISO 11357-2 differential scanning calorimetry, with no crystalline melt endotherm; the glass transition temperature is typically reported between 20 °C and 30 °C, a property that directly controls storage, drying, and sterilization conditions.

These values are raw-material acceptance controls, not finished-device specifications. Because the grade is amorphous and above or near its glass transition at 25 °C, the certificate of analysis is generated under controlled storage and may change if the material is exposed to moisture or heat before testing.

How does ε-caprolactone incorporation alter the degradation profile relative to PLGA and PLLA?

Incorporation of 30 mol% ε-caprolactone replaces glycolide units with a more hydrophobic and flexible aliphatic segment. Because ε-caprolactone-rich sequences do not readily crystallize in this composition, RESOMER LC 703 S remains amorphous and is above its glass transition under physiological conditions. This affects hydrolytic degradation: water ingress is slower than in 50:50 poly(D,L-lactide-co-glycolide), delaying bulk erosion, while the absence of glycolic acid reduces the severity of acid-catalyzed autocatalysis. The ε-caprolactone segments degrade to 6-hydroxyhexanoic acid, which is less acidic and less hydrophilic than glycolic acid, further moderating the local pH drop.

In vitro degradation testing per ASTM F1635-16 uses phosphate-buffered saline at 37 °C and pH 7.4. Under these conditions, 50:50 poly(D,L-lactide-co-glycolide) grades such as RESOMER RG 504 H are commonly reported to exhibit substantial mass loss within 3–6 months, whereas high-molecular-weight semicrystalline poly(L-lactide) may require more than 24 months. Published mass-loss data for the specific LC 703 S configuration are limited; implant developers should verify degradation on the finished geometry rather than extrapolating from granules or films because surface-area-to-volume ratio affects autocatalytic acid accumulation.

Mechanical property differences are equally important. The ε-caprolactone units reduce tensile strength and modulus while increasing elongation compared with semicrystalline poly(L-lactide). Tensile properties are not specified on the raw-material certificate; molded or film specimens are characterized according to ISO 527-2 or ASTM D638-14. Compared with high-molecular-weight polycaprolactone, which degrades over multiple years, LC 703 S retains a substantially faster resorption profile because the lactide-rich segments remain hydrolytically labile.

Moisture removal before melt processing is the primary control point for molecular weight retention. Amorphous lactide-caprolactone granules equilibrate with ambient humidity; residual moisture above <0.05% w/w causes hydrolytic chain scission during extrusion or injection molding. Vacuum drying at 40 °C and <10 mbar for 8–12 h, or dry-air drying with a −40 °C dew point, is used to reach residual moisture below 0.05%; verification is by Karl Fischer titration per ISO 15512. Single-screw extruders with 24:1 to 30:1 L/D and chilled feed throats at 10–20 °C prevent feed-zone bridging, a known failure mode when granules soften before the compression zone. Barrel zone temperatures from 140 °C to 180 °C are typical for the grade; melt temperatures above 200 °C accelerate thermal degradation and should be avoided on production-scale runs.

Injection molding of thin-walled parts uses mold temperatures below the glass transition, typically 15–20 °C, to permit ejection without deformation. For microsphere production, the polymer is dissolved in dichloromethane, and the organic phase is emulsified with an aqueous poly(vinyl alcohol) continuous phase. Residual dichloromethane in the final microspheres is controlled according to Ph. Eur. 2.4.24 or ICH Q3C; particle size distribution is measured by laser diffraction per ISO 13320. Batch-to-batch differences in inherent viscosity within the 1.5–2.5 dL/g range can alter initial release from microspheres; blending of multiple production lots is used to narrow the viscosity distribution.

For solvent-cast films, polymer solutions at 5–15% w/w in dichloromethane are cast onto PTFE or glass substrates; residual solvent is removed by gradual evaporation followed by vacuum drying at 30–40 °C. Film thickness and drying rate influence residual stress and water uptake; thickness is measured according to ISO 4593. Solvent-cast films may exhibit different degradation kinetics than melt-extruded films because thermal history is lower and residual solvent can plasticize the matrix.

Chemical compatibility boundaries are imposed by the ester backbone. Strong aqueous bases, primary and secondary amines, and nucleophilic catalysts accelerate ester cleavage and should not be compounded into the melt unless the resulting molecular-weight loss is explicitly characterized. Non-nucleophilic solvents such as dichloromethane, chloroform, and tetrahydrofuran are used for solution processing; protic solvents such as methanol or ethanol may be used as non-solvents for precipitation or washing but can extract low-molecular-weight fractions.

When Terminal Sterilization Is Applied, Dose Mapping Must Account for the Copolymer's Low Glass Transition

The glass transition of RESOMER LC 703 S lies close to typical ethylene oxide cycle temperatures. Ethylene oxide cycles with chamber temperatures at 30–40 °C can reduce part stiffness and cause sticking or deformation if the device is not restrained; validation should include dimensional checks after exposure and aeration. Ethylene oxide validation per ISO 11135:2014 includes process challenge devices in routine loads; because the polymer is amorphous and hydrophobic, ethylene oxide desorption may be slower than for semicrystalline materials, requiring extended aeration at 30–35 °C to meet residual limits of ISO 10993-7.

Gamma irradiation reduces molecular weight through chain scission. Dose mapping per ISO 11137-2 is required because the absorbed dose distribution within a finished device differs from the raw polymer. Post-sterilization inherent viscosity should be measured and compared with the pre-sterilization value; a specification for minimum post-sterilization viscosity must be derived from device performance data, not from supplier raw-material limits. Devices sterilized at 25 kGy may show reduced molecular weight; the magnitude is geometry- and dose-rate-dependent because radical recombination competes with chain scission in the amorphous matrix. If terminal sterilization is not feasible, aseptic processing is used for drug delivery systems containing heat-labile or radiation-sensitive active pharmaceutical ingredients.

Manufacturing of RESOMER LC 703 S occurs under a quality management system certified to ISO 13485:2016. The batch certificate includes the chemical and physical acceptance limits listed above. Biological evaluation of the raw polymer is addressed through supplier testing according to ISO 10993-1:2018; however, clause 4.1 places responsibility on the device manufacturer for biological evaluation of the final finished device, including leachables, sterilization residuals, and degradation products. Pharmacopoeial methods are applied to specific attributes because the copolymer does not have a dedicated monograph. REACH compliance is declared by the supplier; no substances of very high concern are present above 0.1% w/w.

In drug-eluting implant applications, LC 703 S is used where the active pharmaceutical ingredient is heat-sensitive and cannot survive melt compounding; solvent-based coating or microsphere incorporation is then used. The low glass transition permits conformable coatings but also restricts the upper storage temperature of coated devices to below 25 °C unless structural support or cross-linking is present.

Comparative Placement with Other Medical-Grade RESOMER Copolymers

RESOMER LC 703 S occupies an intermediate position between fast-degrading PLGA copolymers and slow-degrading poly(L-lactide) or polycaprolactone. The following comparison is based on supplier literature and standard characterization methods; degradation times are in vitro approximations and are not finished-device specifications.

The choice between LC 703 S and PLGA is often driven by release duration and mechanical flexibility. For microsphere formulations requiring release beyond 3 months without the stiffness of PLLA, LC 703 S is evaluated. For load-bearing fixation devices where mechanical strength is paramount, semicrystalline PLLA remains preferred; however, its long degradation time and crystalline debris are disadvantageous in soft-tissue applications. The amorphous nature of LC 703 S avoids crystalline particle formation associated with PLLA degradation, a material-selection argument supported by implant retrieval studies.

Storage conditions for LC 703 S follow the same constraints as other amorphous resorbable polyesters. Sealed, dry containers at 2–8 °C are used for long-term retention of molecular weight; repeated warming to ambient temperature without desiccation induces moisture uptake and should be minimized. Because the glass transition is near ambient, granule sintering can occur if bulk packaging is exposed to temperatures above 30 °C during transport or warehouse storage; visual inspection after transport is recommended. Each processing campaign should begin with moisture determination and drying as described above, not with an assumption of stable molecular weight from the certificate of analysis.